

AUTHOR INDEX

- Abella, E., 377
 Achutti, A.C., 143
 Adams, J., 613
 Algranti, E., 143
 Anaissie, E., 577
 Anderson, W.F., 106
 Anderson, K.C., 535, 597, 607
 Ang, P., 419
 Astrow, A.B., 30
- Babu, K.G., 169
 Barlogie, B., 577
 Baynes, R.D., 377
 Bellamy, W.T., 551
 Berenson, J.R., 626
 Berg, C.D., 106
 Bergsland, E.K., 521
 Bladé, J., 588
 Bonadonna, G., 13
 Brannett, C.C. Jr., 487
 Bunnell, C.A., 344
 Burstein, H.J., 344
 Buzdar, A.U., 291
- Campbell, M., 377
 Capri, G., 13
 Champagne, P., 620
 Chauhan, D., 607
 Chay, C., 3
 Cohen, I., 121
 Costa, A., 140
 Curley, S.A., 487
- D'Amato, R.J., 597
 Dammacco, F., 543
 Dansey, R.D., 377
 Davidson, N.E., 322
 de Camargo, E.A., 158
 Dees, E.C., 322
 Desikan, R.K., 593
 Diel, I.J., 236
 Digman, J., 400
 Dupont, E., 620
 Duray, P.H., 570
- El Bolkaity, M.N., 174
 El Malwa, N.G., 174
 Eluf-Neto, J., 188
 Esteve, J., 588
- Falardeau, P., 620
 Figg, W.D., 570
 Fisher, B., 389, 400
 Fisher, E.R., 400
 Folkman, J., 536
 Fong, Y., 460, 474
 Foon, K.A., 68
 Frigeri, A., 543
- Ganz, P.A., 274
 Garber, J., 419
 Ghavamzadeh, A., 153
 Gianni, L., 13
 Giuliano, A.E., 41
- Habal, N., 41
 Hamm, C., 377
 Hariton, C., 620
 Harris, D.T., 1
 Hawk, E., 106
 Hayes, D.F., 53
 Hideshima, T., 607
 Hortobagyi, G.N., 284
- Iravani, M., 153
 Isaacs, C., 53
- Jagannath, S., 593
 Jahani, M., 153
 Jochelson, M., 221
 Johnson, P.J., 503, 514
 Jordan, V.C., 260
- Kashef, E., 497
 Khaled, H.M., 174
 Klein, J.L., 377
 Krag, D., 229
 Kruger, E.A., 570
 Kyle, R.A., 560, 583
- Land, S., 400
 Lentzsch, S., 597
 Leung, T.W.T., 503, 514
 Little, S.A., 460, 474
 Los, M., 93
- Ma, H.M., 626
 Macdonald, J.S., 30
 Mamounas, E., 400
 Mamounas, E.P., 389
 Mamounas, T., 219
 Menezes, A.M.B., 143
 Moliterni, A., 13
 Monro, A., 441
 Montoto, S., 588
 Montserrat, E., 588
 Morton, D.L., 41
 Moussavi, A., 153
 Munshi, N.C., 565
 Muss, H.B., 313
- Nascimento, C.M.R., 188
- O'Regan, R.M., 260
 Ogunbiyi, J.O., 179
- Paik, S., 305, 332
 Park, C., 332
 Perales, M., 588
 Peters, W.P., 377
 Plesnicar, A., 210
 Plesnicar, S., 139, 210
 Pluda, J.M., 570
 Podar, K., 607
 Poyet, P., 620
 Price, D.K., 570
- Rajkumar, S.V., 560, 583
 Rastegarpanah, M., 153
 Recht, A., 245
 Ribatti, D., 543
 Richardson, P., 607
 Roberts, J.P., 497
 Roccaro, A.M., 543
 Rogers, M.S., 597
 Rosinol, L., 588
- Safa, M.M., 68
 Schlossman, R.L., 607
 Sherman, M., 450
 Smith, D.C., 3
 Stearns, V., 53
 Stirling, D., 602
 Swain, S., 219
 Swain, S.M., 359
- Tagliaferri, M., 121
 Tan, A.R., 359
 Tan-Chiu, E., 253
 Theriault, R.L., 284
 Thomas, J.O., 198
 Tomatis, L., 207
 Tricot, G., 577
 Tripathy, D., 121
 Tuser, M., 588
- Vacca, A., 543
 Valagussa, P., 13
 Venook, A.P., 439
 Vescio, R., 626
 Voest, E.E., 93
- Wünsch-Filho, V., 158
 Warren, R.S., 439
 Wickerman, D.L., 253
 Wilson, C., 565
 Winer, E.P., 344
 Wolmark, N., 400
 Wright, T.L., 441
- Zambetti, M., 13
 Zwiebel, J.A., 336

AUTHOR INDEX

- Abella, E., 377
 Achutti, A.C., 143
 Adams, J., 613
 Algranti, E., 143
 Anaissie, E., 577
 Anderson, W.F., 106
 Anderson, K.C., 535, 597, 607
 Ang, P., 419
 Astrow, A.B., 30
- Babu, K.G., 169
 Barlogie, B., 577
 Baynes, R.D., 377
 Bellamy, W.T., 551
 Berenson, J.R., 626
 Berg, C.D., 106
 Bergsland, E.K., 521
 Bladé, J., 588
 Bonadonna, G., 13
 Branett, C.C. Jr., 487
 Bunnell, C.A., 344
 Burstein, H.J., 344
 Buzdar, A.U., 291
- Campbell, M., 377
 Capri, G., 13
 Champagne, P., 620
 Chauhan, D., 607
 Chay, C., 3
 Cohen, I., 121
 Costa, A., 140
 Curley, S.A., 487
- D'Amato, R.J., 597
 Dammacco, F., 543
 Dansey, R.D., 377
 Davidson, N.E., 322
 de Camargo, E.A., 158
 Dees, E.C., 322
 Desikan, R.K., 593
 Diel, I.J., 236
 Digman, J., 400
 Dupont, E., 620
 Duray, P.H., 570
- El Bolkaity, M.N., 174
 El Malwa, N.G., 174
 Eluf-Neto, J., 188
 Esteve, J., 588
- Falardeau, P., 620
 Figg, W.D., 570
 Fisher, B., 389, 400
 Fisher, E.R., 400
 Folkman, J., 536
 Fong, Y., 460, 474
 Foon, K.A., 68
 Frigeri, A., 543
- Ganz, P.A., 274
 Garber, J., 419
 Ghavamzadeh, A., 153
 Gianni, L., 13
 Giuliano, A.E., 41
- Habal, N., 41
 Hamm, C., 377
 Hariton, C., 620
 Harris, D.T., 1
 Hawk, E., 106
 Hayes, D.F., 53
 Hideshima, T., 607
 Hortobagyi, G.N., 284
- Iravani, M., 153
 Isaacs, C., 53
- Jagannath, S., 593
 Jahani, M., 153
 Jochelson, M., 221
 Johnson, P.J., 503, 514
 Jordan, V.C., 260
- Kashef, E., 497
 Khaled, H.M., 174
 Klein, J.L., 377
 Krag, D., 229
 Kruger, E.A., 570
 Kyle, R.A., 560, 583
- Land, S., 400
 Lentzsch, S., 597
 Leung, T.W.T., 503, 514
 Little, S.A., 460, 474
 Los, M., 93
- Ma, H.M., 626
 Macdonald, J.S., 30
 Mamounas, E., 400
 Mamounas, E.P., 389
 Mamounas, T., 219
 Menezes, A.M.B., 143
 Moliterni, A., 13
 Monro, A., 441
 Montoto, S., 588
 Montserrat, E., 588
 Morton, D.L., 41
 Moussavi, A., 153
 Munshi, N.C., 565
 Muss, H.B., 313
- Nascimento, C.M.R., 188
- O'Regan, R.M., 260
 Ogunbiyi, J.O., 179
- Paik, S., 305, 332
 Park, C., 332
 Perales, M., 588
 Peters, W.P., 377
 Plesničar, A., 210
 Plesničar, S., 139, 210
 Pluda, J.M., 570
 Podar, K., 607
 Poyet, P., 620
 Price, D.K., 570
- Rajkumar, S.V., 560, 583
 Rastegarpanah, M., 153
 Recht, A., 245
 Ribatti, D., 543
 Richardson, P., 607
 Roberts, J.P., 497
 Roccaro, A.M., 543
 Rogers, M.S., 597
 Rosiñol, L., 588
- Safa, M.M., 68
 Schlossman, R.L., 607
 Sherman, M., 450
 Smith, D.C., 3
 Stearns, V., 53
 Stirling, D., 602
 Swain, S., 219
 Swain, S.M., 359
- Tagliaferri, M., 121
 Tan, A.R., 359
 Tan-Chiu, E., 253
 Theriault, R.L., 284
 Thomas, J.O., 198
 Tomatis, L., 207
 Tricot, G., 577
 Tripathy, D., 121
 Tuser, M., 588
- Vacca, A., 543
 Valagussa, P., 13
 Venook, A.P., 439
 Vescio, R., 626
 Voest, E.E., 93
- Wünsch-Filho, V., 158
 Warren, R.S., 439
 Wickerman, D.L., 253
 Wilson, C., 565
 Winer, E.P., 344
 Wolmark, N., 400
 Wright, T.L., 441
- Zambetti, M., 13
 Zwiebel, J.A., 336

SUBJECT INDEX

- Ablation
 in hepatocellular carcinoma, 499-500
 radiofrequency, *see* Radiofrequency ablation
- Acrolein, 339
- Acupuncture, 125, 126
- Adenoviral death protein, 337-338
- Adenovirus, 340
 safety of, as cancer therapy, 341
- Adjuvant chemotherapy
 in all breast cancer, 369-370
 clinical studies of, 7-8
 guidelines for, 372
 high-dose, 19
 neoadjuvant *v.*, 394
 overview of, 359-360
 potential toxicities of, 370
 side effects of, 370-372
- Adjuvant endocrine therapy
 benefits of, 319-320
 patient selection for, 313-314
- Adjuvant Tamoxifen-Longer Against Shorter Trial, 261
- Adjuvant Tamoxifen-Treatment Offer More Trial, 261
- Adjuvant therapy
 in breast cancer, 13-20
 in hepatocellular carcinoma, 478
 in prostate cancer, 3-4
 recently closed trials of, in colorectal cancer, 35
 standard of care, in colorectal cancer, 35
- Adrenalectomy, 293
- Aflatoxin, 444, 446
 as hepatocellular carcinoma risk, 181
- Africa
 bladder cancer in, 174
 hepatocellular carcinoma incidence in, 180
 hepatocellular carcinoma morphology in, 183
 sub-Saharan, *see* Sub-Saharan Africa
- AG3340, 96, 571
- Age, ipsilateral breast tumor recurrence and, 414
- Air pollution, lung cancer and, 148
- Alcohol
 as cancer risk factor, 164
 hepatitis virus and, 444
 hepatocellular carcinoma and, 443
- Alcoholic cirrhosis, hepatocellular carcinoma and, 443
- Alendronate, 285, 286
- Allogeneic whole-cell vaccine, 72
- Alopecia, associated with adjuvant chemotherapy, 370-372
- Alpha tocopherol, 113, 123
- Alpha-1-antitrypsin, deficiency of, 444-445
- Alpha-fetoprotein
 following PLAF regimen, 517
 in hepatocellular carcinoma surveillance, 453
- Alternative medicine, definition of, 121-122
- Aminoglutethimide, 268, 297-298
- Aminothalidomide, 3-, 599
- Anal cancer, in sub-Saharan Africa, 203
- Anastrozole, 268, 298-299, 318-319
- Androgen, in postmenopause, 293
- Androstenedione, 268
- Angelica sinensis*, 128, 129
- Angiogenesis
 definition of, 560
 ipsilateral breast tumor recurrence and, 414
 marker of, 60-61
 measurement of, 597
 in multiple myeloma, 561-562
 process of, 94
 prognostic factors and, 94-95
 prognostic value of, in myeloma, 562
 of tumors, 93-94
- Angiogenesis inhibitor, thalidomide as, 537-538
- Angiogenesis-dependent disease, leukemias as, 536, 537
- Angiogenic growth factor, in human hematopoietic tumor cell lines, 555
- Angiography, in hepatocellular carcinoma, 467
- Angiostatin, 95, 571
- Anthracycline
 liposomal, 348-349
 non-anthracycline regimens *v.*, in breast cancer, 362-364
- Anti-epithelial membrane antigen, 238
- Anti-idiotypic antibody, 82-84
- Anti-idiotypic vaccine, 72
- Anti-vascular endothelial growth factor antibody, 96
- Antiangiogenesis agents, in hepatocellular carcinoma, 508-509
- Antiangiogenic agent(s)
 in cancer adjuvant therapy, 100-101
 chemotherapy plus, 100
 clinical use of, 97-100
 drug resistance and, 98-99
 evaluation of, 99
 route of administration for, 99
 screening of, endothelial cell assay for, 570-572
 side effects of, 98
- Antiangiogenic therapy, 95-97
 in cancer perioperative therapy, 101-102
- Antibody(ies)
 anti-idiotypic, 82-84
 to cytoskeleton keratins, 238
 to membrane-bound surface antigens, 238
- Antibody-dependent cellular cytotoxicity, 69
- Antigen-presenting cell, 73
- Antihormonal therapy, in hepatocellular carcinoma, 517-518
- Antioxidant, as chemopreventive agent, 110
- Antisense trial, in cancer, 337
- Antivascular therapy, 95-97
- Aorta, thoracic rat, 572
- Aortic ring angiogenesis assay, Matrigel rat, 571-573
- Apoptotic index, ipsilateral breast tumor recurrence and, 414
- Aquaporin 1, 544-546
- Argentina
 occupations in, and lung cancer, 148
 Pap smear testing in, 194
- Arsenic, lung cancer and, 147

- Arteriogram, hepatic, in hypervascular hepatocellular carcinoma, 467
- Arteriography, direct CT, 465
- Arteriportography, CT, 465
- Asatine-211, 70
- Asbestos, Brazilian worker exposure to, 149
- Ascorbic acid, 113
- Asia, hepatocellular carcinoma incidence in, 180
- Astragalus membranaceus* Bunge, 128, 129
- Ataxia-telangiectasia, breast cancer risk and, 423
- Autologous tumor vaccine, 72
- Axillary lymph node dissection
 - in breast cancer, 45
 - for breast cancer staging, 236-237
 - routine, 46
- Axillary lymph node status
 - in breast cancer, 21-22
 - locoregional failure and, 247
 - as prognostic factor, 55-56
- Axillary sentinel lymphadenectomy, development of, 47

- B72, radiolabeled chimeric, 72
- Bacterial carboxypeptidase, 339
- Basic fibroblast growth factor, 61, 508
 - angiogenesis and, 536
- Batimastat, 98
- Bcl2 family, 63-64
- Bcl-2* expression, ipsilateral breast tumor recurrence and, 414
- BEC2, 84
- Beedis, 170
- Behavior modification, in cancer prevention, 253
- Beta-carotene, 109-110, 123
- Betel leaf, 170
- Betel nut, 170
- Bevacizumab, 571
- Bilharzial cystitis, in Egypt, 174
- Biomarkers, tumor response and, 394
- Bismuth-212, 70
- Bisphosphonate(s)
 - adjuvant, in advanced breast cancer, 369
 - analogs of, 285
 - clinical uses of, 285
 - definition of, 284
 - impact of, on bone, 284
 - mechanism of action of, 284
 - pharmacokinetics of, 284-285
 - structure of, 285
- Bladder cancer
 - in Africa, 174
 - biologic aspects of, 175-176
 - chemotherapy in, 177
 - clinical picture in, 176
 - future directions in, 178
 - pathology of, 174-175
 - treatment of, 176-178
 - types of, 176
- Bleomycin, doxorubicin regimen, in hepatocellular carcinoma, 515
- Blue dye, for intraoperative mapping, 48
- BMS-275291, 571, 96
- Bone, metastasis to, 286
- Bone density, tamoxifen and, 263-264
- Bone marrow, microvessel density in, poor prognosis and, 565-566
- Bone marrow angiogenesis, 543-544
 - measurement of, 560-561
 - multiple myeloma therapy and, 562-563
 - as prognostic marker, 549-550
- Bone marrow micrometastasis, 59-60
- Bone marrow staging
 - in breast cancer, 238
 - of cancer, v lymph node status, 241
- Bone metastasis, prevention of, 288
- Boyden chamber technique, 546
- Brazil
 - cigarette consumption in, 146
 - lung cancer in, 143-144
 - mouth cancer in, 160
 - occupation in, and lung cancer, 148
 - occupational categories in, 149
 - Pap smear testing in, 194
 - pharyngeal cancer in, 160
 - smoking in, 145-147
- BRCA1 gene, 421-422
- BRCA1 mutation
 - penetrance of, 424
 - prevalence of, 422-424
 - testing for, 425
- BRCA2 gene, 421-422
- BRCA2 mutation
 - penetrance of, 424
 - prevalence of, 422-424
 - testing for, 425
- Breast cancer
 - adjuvant treatment in, 13-20
 - advanced, chemotherapy in, 344-345
 - in all patients, 369-370
 - anthracycline v non-anthracycline-based regimens in, 362-364
 - chemoprevention of, 254-255, 428-429
 - chemotherapy dose response in, 381-382
 - chemotherapy outcomes in, 378-379
 - diagnosis of, options with, 429
 - diet in, 123-124
 - early-stage, adjuvant endocrine therapy benefits in, 313-314, 319-320
 - endocrine therapy of, 292-293
 - estrogen levels and, 277
 - family history of, 420-421
 - gemcitabine in, 352
 - genetic testing for, 425-427
 - genetics in, 421-425
 - hematopoietic stem cell transplantation in, 379-381
 - high-dose chemotherapy in, 367-369, 379-381, 382-384
 - high-risk primary, 381-384
 - historical overview of, 13
 - incidence of, 419
 - international overview of, 13-15
 - invasive, 255
 - local relapse in, 23-24
 - locally advanced, 384
 - menopause and, 277

- Breast cancer (*Continued*)
 metastatic, 378-381
 mind-body approaches in, 124
 mutation testing for, 425, 429
 natural history of, 291-292
 neoadjuvant chemotherapy in, 389-390
 neoadjuvant chemotherapy trials in, 390-391
 neoadjuvant therapy in, 20-24
 newer strategies in, 17-20
 ovarian ablation in, 314-315
 polychemotherapy in, 15
 prevention modalities for, 253-254
 prevention of, 428
 prognostic factors in, 53-55
 relapse-free survival in, 22, 23
 relative risk for, 276
 selective estrogen receptor modulator in, 264
 sentinel lymph node dissection in, 45-50
 stem cell transplantation in, 382-384
 subclinical, tamoxifen and, 255
 surgery in, 24
 systemic adjuvant therapy of, late effects from, 25-26
 tamoxifen in, 315-318
 therapy selection in, 292
 treatment goals of, 292
 Breast Cancer Prevention Trial, 253
 Breast cancer risk, estimating, 419-421
 Breast cancer survivor(s)
 estrogen use in, 281
 menopausal symptom management in, 279-282
 menopausal syndromes in, 277-279
 Breast-conserving surgery, increasing rate of, 394
 Bromodeoxyuridine incorporation of, 57-58
 Buserelin, 323
 Bystander effect, 338-340
- c-erbB-2, 26, 60
 CAD technique, 222, 223
 Cancer
 detection of, studies of, 239
 early systemic therapy in, 1-2
 future of, in emerging world, 210-213
 hormonal aspects of, 254
 hypercalcemia associated with, 285-286
 prognostic factors in, 238-240
 surveillance for, 450
 tumor in, onion skinning of, 338
 world control of, 140
 Cancer education, in emerging world, 214
 Cancer risk, inequalities in, 207-208
 Cancerization, field, 108
 Capecitabine, 349, 350, 515
 in hepatocellular carcinoma, 508
 Carbohydrate antigen, tumor-associated, 80-81
 Carbohydrate vaccine, 72, 80-81
 Carboplatin
 high-dose, 19
 with taxanes, 348
 Carboxyamidotriazole, 571
 Carboxyaminoimidazole, 96, 97
- Carcinoembryonic antigen, recombinant vaccine expressing, 81-82
 Carcinogenesis, multistep, 107-108
 Cardiomyopathy, associated with adjuvant chemotherapy, 370-372
 Carmustine, high-dose, 19
 Carotenoids, as chemopreventive agents, 109-110
 Carribean, cancer incidence rates in, 159
 Cathepsin D, 61-62
 CB1954 prodrug, 339
 CD4 helper T cell, 73
 CD40L antibody, 338
 CDC-501, 605
 CeaVac, 83
 Cell death, marker of, 63
 Central America, cancer incidence rates in, 159
 Cervical cancer
 human papillomavirus and, 190-191
 Latin American incidence of, 188-189
 oral contraceptives and, 192-193
 reproductive history and, 192
 screening for, 193-195
 sexual behavior and, 191-192
 socioeconomic status and, 192
 in sub-Saharan Africa, 202-203
 in Uganda, 203
 worldwide incidence of, 188-189
 worldwide mortality due to, 189-190
 CGP-41251, 571
 CGS-270223A, 571
 Challenge, 142
 Chemoembolization
 in hepatocellular carcinoma, 500, 505
 pretransplant intrahepatic transarterial, 447
 Chemoprevention, 253-254
 of breast cancer, 254-255
 carotenoids in, 109-110
 definition of, 253
 Chemoprotection, 348
 trials of, 337
 Chemoresistance, in multiple myeloma, 628
 Chemotherapy
 adjuvant, see *Adjuvant chemotherapy*
 in advanced breast cancer, 344-345
 antiangiogenic agent with, 100
 in bladder cancer, 177
 combination, in hepatocellular carcinoma, 515-516
 dose intensification of, in breast cancer, 364-365
 in esophageal cancer, 155
 high-dose, see *High-dose chemotherapy*
 menopause and, 275
 neoadjuvant, see *Neoadjuvant chemotherapy*
 non-cross-resistant regimens of, in breast cancer, 17
 outcomes of, in metastatic breast cancer, 378-379
 ovarian ablation plus, 327-328
 ovarian ablation v, 326-327
 ovarian failure and, 324
 poly-, see *Polychemotherapy*
 in postmenopausal women, 360-362
 postoperative v primary, 22
 in premenopausal women, 314-315

- Chemotherapy (*Continued*)
 preoperative, *see* Neoadjuvant chemotherapy
 PS-341 and, 630
 response to, prediction of, 21
 sequencing of, and radiation therapy, 24-25
 single-agent, in hepatocellular carcinoma, 514-515
 systemic, in hepatocellular carcinoma, 506-507
 tamoxifen and, in early-stage breast cancer, 318
 trastuzumab and, 352-353
- Chick embryo chorioallantoic membrane assay, 574-575
- Child-Pugh classification system, 475
- China, esophageal cancer in, 154
- Chinese herbal therapy, 127
- Chinese medicine, traditional, 124-129
- Chloroquine, 540
- Cholesterol level, tamoxifen and, 263-264
- Chorioallantoic membrane, chick embryo, 547
- Chorioallantoic membrane assay, chick embryo, 574-575
- Cigarettes, consumption of, in Brazil, 146
- Cinnamomum cassia* Blume, 128, 129
- Cirrhosis, 451-452
 alcoholic, hepatocellular carcinoma and, 443
 CT in, 469
 dysplastic nodules in, 462
 dysplastic nodules' natural history in, 462-463
 as hepatocellular carcinoma risk, 182-183
 hepatocellular carcinoma and, 441, 443, 503-504, 522-523
 nodular lesions in, MRI of, 466-467
 regenerative nodules in, 461-462
- Cisplatin, 515
 in hepatocellular carcinoma, 504
 high-dose, 19
 with taxanes, 348
- Cisplatin, doxorubicin, fluorouracil, interferon- α 2b
 regimen, in hepatocellular carcinoma, 515-517
- Cisplatin, interferon- α 2b regimen, in hepatocellular
 carcinoma, 515
- Cisplatin, methotrexate, fluorouracil, interferon- α 2b
 regimen, in hepatocellular carcinoma, 515
- Claus model, 420, 421
- Clinical trial, prediction-based, 307-308
- Clodronate, 285, 286, 287, 369
- Clofazimine, in hepatocellular carcinoma, 515
- Coenzyme Q 10, 123
- Cognitive dysfunction, associated with adjuvant
 chemotherapy, 370-372
- COL-3, 571, 96
- Colony-stimulating growth factor, myelosuppression and, 18
- Colorectal cancer
 adjuvant therapy background in, 30-32
 future therapy directions in, 36-38
 incidence of, 30, 68
 standard of care adjuvant therapy programs in, 35
 surgical stage in, and survival, 31
- Combination chemotherapy, in hepatocellular carcinoma,
 515-516
- Combretastatin, 571, 96
- Comedonecrosis, ipsilateral breast tumor recurrence and, 414
- Complementary medicine, definition of, 121-122
- Computed tomography
 in cirrhosis, 469
- Computed tomography (*Continued*)
 contrast-enhanced, in hepatocellular carcinoma, 461
 direct, arteriography, 465
 in hepatocellular carcinoma, 463-465
 lipiodol, 464
 in recurrent hepatocellular cancer, 492
- Computed tomography arteriography, 465
- Computer-aided detection and diagnosis, 222, 223
- Connexin 43, 338
- Copper-67, 70
- Core needle biopsy, neoadjuvant chemotherapy and, 395
- Core protein, hepatitis C, 523-524
- Cornea micropocket assay, 574
- Coronary artery disease, relative risk for, 276
- Costa Rica, Pap smear testing in, 194
- Couch model, 426
- Cowden syndrome, breast cancer risk and, 423
- CPT-11, 37
- Cryoablation, in hepatocellular carcinoma, 489-490
- Cryosurgery, 506
 in hepatocellular carcinoma, 482
- CT, *see* Computed tomography
- CTLA4Ig, 338
- Cyclin D1, ipsilateral breast tumor recurrence and, 414
- Cyclo-oxygenase, 102
- Cyclophosphamide
 adjuvant, 25
 in breast cancer, 14-15
 cyclophosphamide, methotrexate, fluorouracil regimen *v*,
 334
 dose intensification of, in breast cancer, 364-365
 doxorubicin, cyclophosphamide regimen *v*, 334
 doxorubicin regimen, 305-306
 in early-stage breast cancer, 315, 316
 HER-2 overexpression and, 332-333
 high-dose, 19
 in metastatic breast cancer, 17
 in postmenopausal women, 360-362
 taxanes plus, 348
 trials of, 326, 327
 20-year results following, 16
- Cyclophosphamide, methotrexate, fluorouracil regimen,
 locoregional failure and, 248-249
- Cyclophosphamide, methotrexate, fluorouracil, prednisone,
 tamoxifen regimen, 249
- Cyproterone acetate, in neoadjuvant therapy trials, 9
- Cytochrome p450 gene, 339
- Cytokines, thalidomide effects on, 600
- Cytoreduction, limit of, mechanisms responsible for, 305
- Cytosine deaminase, 339
- D-99, 348-349
- Daunorubicin, liposomal, in hepatocellular carcinoma, 515
- Dendritic cell, 73, 84-85
- Developing countries, 141
- Dexamethasone, thalidomide plus, 585-586
- Dexrazoxane, doxorubicin regimen, with taxanes, 348
- Diabetes, relative risk for, 276
- Diarrhea, 34
- Diet
 in breast cancer, 123-124

- Diet (*Continued*)
 as cancer risk factor, 164-165
 Dietary supplement, in breast cancer, 123-124
 Diethylstilbestrol, in prostate cancer, 5-7
 Diferuloyl methane, 110
 as chemopreventive agent, 109
 Differential absorption ratio, 226
 Differentiation marker, 111
 Digital mammography, full-field, 221
 Dihydropyrimidine dehydrogenase, 349
 Dinitrophenyl vaccine, 75
 District Cancer Control Program, in India, 171-172
 Djerba Statement, 142
 DNA binding, nuclear factor-kB and, 628-629
 DNA flow cytometry, 57
 DNA ploidy, ipsilateral breast tumor recurrence and, 414
 DNA synthesis, measurement of, 599
 DNA vaccine, 72
 Docetaxel, 345, 396
 in advanced breast cancer, 365-366
 dosing of, 346
 in metastatic breast cancer, 346-347
 weekly, phase II trial of, 347
 Double target effect, 541
 Doxil, 349
 with taxanes, 348
 Doxocycline, liposomal, 349
 Doxorubicin, 348, 514, 515
 in chemotherapy regimen, for breast cancer, 16
 cyclophosphamide, methotrexate, fluorouracil regimen v, 334
 dose intensification of, in breast cancer, 364-365
 in early-stage breast cancer, 315, 316
 in hepatocellular carcinoma, 504, 506, 515, 516-517
 locoregional failure and, 248
 in metastatic breast cancer, 17
 regimens containing, and HER-2 overexpression, 333-334
 taxanes plus, 348
 trials of, 326, 327
 Doxorubicin, bleomycin regimen, in hepatocellular carcinoma, 515
 Doxorubicin, cyclophosphamide regimen, 305-306
 Doxorubicin, dexrazoxane regimen, with taxanes, 348
 Doxorubicin, fluorouracil, methyl-CCNU regimen, in hepatocellular carcinoma, 515
 Doxorubicin, fluorouracil, mitomycin regimen, in hepatocellular carcinoma, 515
 Droloxifene, 266, 296
 Ductal carcinoma in situ, 400-402
 Dysplastic nodule, in cirrhosis, 462-463, 466

 E-cadherine expression, ipsilateral breast tumor recurrence and, 414
 Edetrexate, 350
 with taxanes, 348
 Egypt, bladder cancer in, 174
 Elective lymph node dissection, 41-42
 EM 652, 267
 EM 800, 267
 EMD121974, 96, 571
 Emerging world, 141

 Emesis, associated with adjuvant chemotherapy, 370-372
 Endocrine therapy
 adjuvant, see Adjuvant endocrine therapy
 of breast cancer, 292-293
 mechanism of action of, 293
 selection of, 293-294
 sequences of, for metastatic breast cancer, 295
 types of, 294-301
 Endometrial cancer, tamoxifen and, 263-264
 Endostatin, 96, 540, 571
 Endothelial cell
 growth inhibition of, 95
 lymphatic, 230
 Endothelial cell assay, in antiangiogenic agent screening, 570-572
 Eniluracil, fluorouracil with, 349, 350
 Environment, cancer risk factors in, 165-166
 Enzyme-linked immunosorbent assay, 60
 Eosin-stained slide, 58
 Epidoxorubicin, 515
 in hepatocellular carcinoma, 514
 Epidoxorubicin, etoposide regimen, in hepatocellular carcinoma, 515
 Epigallocatechin gallate, 110
 as chemopreventive agent, 109
 Epirubicin, 19-20, 348
 in hepatocellular carcinoma, 504
 in metastatic breast cancer, 17
 preoperative, in breast cancer, 334
 Epithelial membrane antigen, anti-, 238
 Escherichia coli nitroreductase, 339
 Esophageal cancer
 in China, 154
 diagnosis of, 154-155
 epidemiology of, 153-154
 etiology of, 154
 in Iran, 153
 staging of, 154-155
 treatment of, 155-156
 Estramustine
 in neoadjuvant therapy trials, 9
 in prostate cancer, 7-8
 Estrogen
 in menopause, 293
 total blockade of, 315
 Estrogen level, breast cancer and, 277
 Estrogen receptor, ipsilateral breast tumor recurrence and, 414
 Estrogen receptor modulator, selective, 260
 Estrogen receptor-negative tumor, 314
 tamoxifen in, 314
 Estrogen receptor-positive tumor, 315
 adjuvant endocrine therapy in, 313-314
 Ethanol injection, percutaneous, 481, 487-488
 Eridronate, 285, 286
 Etoposide
 in hepatocellular carcinoma, 515
 oral, 352
 Etoposide, epidoxorubicin regimen, in hepatocellular carcinoma, 515
 Etretinate, 113

- Exemestane, 268, 300-301, 318-319
with taxanes, 348
- Factor VIII-related antigen, 544
immunoperoxidase staining of, 545
- Fadrozole, 299
- Familial breast and ovarian cancer syndrome, 423
- Faslodex, 267, 297
- Ferumoxide, MRI and, in hepatocellular carcinoma, 467
- Fetal mouse bone explant angiogenesis assay, 575
- Fibroblast growth factor, basic, 508
- Fibroblast growth factor-2, 547-548
- Fibrosis, ipsilateral breast tumor recurrence and, 414
- Field cancerization, 108
- Fine needle aspiration, false-positive risk of, 394-395
- Floxuridine, in hepatocellular carcinoma, 504
- Fluorescence in situ hybridization, 60
- Fluorine-18-labeled deoxyglucose, positron emission tomography with, 226
- Fluorouracil, 37
adjuvant, 25
in breast cancer, 14-15
in colorectal cancer, 31-32
dose intensification of, 364-365
doxorubicin, cyclophosphamide regimen v, 334
in early-stage breast cancer, 315, 316
eniluracil with, 349, 350
in hepatocellular carcinoma, 504, 506, 515, 516-517
HER-2 overexpression and, 332-333
interferon regimen, in hepatocellular carcinoma, 515
leucovorin plus, 32-35
in metastatic breast cancer, 17, 350
oral, analogs of, 349-350
in postmenopausal women, 360-362
trials of, 326, 327
20-year results following, 16
- Fluorouracil, cyclophosphamide, methotrexate, prednisone, tamoxifen regimen, 249
- Fluorouracil, cyclophosphamide, methotrexate regimen, locoregional failure and, 248-249
- Fluorouracil, doxorubicin, methyl-CCNU regimen, in hepatocellular carcinoma, 515
- Fluorouracil, doxorubicin, mitomycin regimen, in hepatocellular carcinoma, 515
- Fluorouracil, folinic acid regimen
in hepatocellular carcinoma, 515
with taxanes, 348
- Fluorouracil, methotrexate, cisplatin, interferon-alpha 2b regimen, in hepatocellular carcinoma, 515
- Fluoxymesterone, in chemotherapy regimen, for breast cancer, 16
- Flutamide
in neoadjuvant therapy trials, 9
in prostate cancer, 8
- Folinic acid, 506
in hepatocellular carcinoma, 504
- Folinic acid, fluorouracil regimen, in hepatocellular carcinoma, 515
- Formestane, 268, 300
- Frank model, 426
- Ftorafur, 36
- Fulvestrant, 319
- Fusogenic membrane glycoprotein, 337, 339
- Gadolinium, 225
- Gail model, 256, 419-420
- Ganciclovir, bystander killing and, 338-340
- Ganglioside, 81
definition of, 69
- Gemcitabine, 351
phase II trials of, in advanced breast cancer, 352
with taxanes, 348
- Gene marking, of tumor cells, 336
- Gene therapy
barriers to, 337-340
in breast cancer, 341
- Gene therapy trial
in cancer, 336
protocols for, 336-337
- Gene transfer, limited, 337-338
- General Electric Sonograph, 221
- Genetic syndrome, increased breast cancer risk and, 423
- Genetic testing
breast cancer risk and, 425-427
informed consent for, 427
insurance and, 429-430
privacy issues and, 429-430
- Genomic marker, 111
- Glycyrrhiza *glabra* L., 128, 129
- Gold, colloidal, 230
- Goserelin, 323
clinical trials of, 326
key trials of, 316
in ovarian ablation, 315
in prostate cancer, 7
- Granulocyte-macrophage colony-stimulating factor, 19
- Green tea, 123
- Hapten, 75
- Heart and Estrogen-Progestin Replacement Study, 276
- Heat treatment, of hepatic malignancy, 490-493
- Hematologic function, acupuncture and, 126
- Hematopoietic stem cell transplantation
five-year metastatic breast cancer survival following, 379
five-year survival following, 382
in high-risk primary breast cancer, 382-384
in locally advanced breast cancer, 384
in metastatic breast cancer, 379-381
overview of, 377-378
- Hematoxylin and eosin-stained slide, 58
- Hemochromatosis, 444, 446
- Hepatectomy, in hepatocellular carcinoma, 475-477
- Hepatic arterial chemoembolization, 488, 489
- Hepatic intra-arterial chemotherapy, 504
- Hepatic malignancy, heat treatment of, 490-493
- Hepatic resection
operative mortality following, 476
radio-labeled lipiodol following, 478
survival rates of, 477
- Hepatitis B, 451
prevention of, 445-446
- Hepatitis B virus, 181-182, 441-442, 524-528

- Hepatitis B virus, 181-182, 441-442, 524-528 (*Continued*)
 alcohol plus, 444
 hepatitis C virus coinfection with, 443-444
Hepatitis Be antigen, 442
Hepatitis C, 451
 prevention of, 446
Hepatitis C core protein, 523-524
Hepatitis C virus, 182, 442-443, 523
 alcohol plus, 444
 hepatitis B virus coinfection with, 443-444
Hepatitis D virus, 182, 443
Hepatocarcinogenesis, 527-528
Hepatocellular carcinoma
 ablation in, 499-500
 adjuvant therapy in, 478
 age and, 180
 antiangiogenesis agents in, 508-509
 antihormonal therapy for, 517-518
 capecitabine in, 508
 chemoembolization in, 500, 505
 childhood, relative ratio frequencies of, 184
 cirrhosis and, 503-504, 522-523
 cryoablation in, 489-490
 cryosurgery in, 482, 506
 curative hepatic resection in, 474
 detection of, imaging accuracy in, 470
 determining extent of, 474-475
 determining functional liver reserve in, 475
 epidemiology in, 179-180, 441-445
 fibrolamellar, MRI of, 468
 genomic instability in, 528-529
 global incidence of, 442
 guided percutaneous biopsy of, 468-469
 hepatectomy in, results of, 475-477
 hepatic arterial chemoembolization in, 488, 489
 hepatic intra-arterial chemotherapy in, 504
 hypervascular, arteriogram of, 467
 imaging screening for, 470
 incidence of, 180, 441, 497, 521-522
 in infancy, 183-184
 integrated imaging approach to, 470-471
 interferon therapy in, 507-508, 518
 introduction to, 439-440
 key imaging points in, 470
 morphology of, in Africa, 183
 MRI in, 467
 neoadjuvant therapy in, 477-478
 octreotide in, 509
 orthotopic liver transplantation in, 479-481
 overview of, 460
 pathology of, 497-498
 patient management in, 500-501
 percutaneous ethanol injection in, 487, 505
 PIAF regimen in, 516-517
 prevention of, 509
 primary prevention of, 445-447
 radiation therapy in, 505-506
 radiofrequency ablation in, 481-482, 491-493
 radiologic staging of, 469-470
 radiological aspects of, 460-461
 radiological imaging in, 498-499
Hepatocellular carcinoma (*Continued*)
 resection in, 499
 risk factors for, 180-183, 452
 ruptured, 468
 secondary prevention of, 447
 single-agent chemotherapy for, 514-515
 surgical suitability in, 475
 surveillance program criteria for, 450
 systemic chemotherapy in, 506-507
 tamoxifen in, 507
 thermotherapy in, 506
 TNM staging of, 469
 transplantation for, 500
 UFT in, 508
 without cirrhosis, 467-468
Hepatocyte, 460
HER-2, 60
Herbal agent, 128
Herbal therapy, traditional Chinese, 127
Herpes simplex virus thymidine kinase gene transfer, 336, 337
Herpes virus, 340
HER-2 gene
 description of, 332
 overexpression of, 332-333
HER-2 gene amplification, tamoxifen and, 314
HER-2 overexpression
 cyclophosphamide, methotrexate, fluorouracil regimen and, 332-333
 doxorubicin-containing regimens and, 333-334
High-dose chemotherapy, 18-19
 in advanced breast cancer, 367-369
 five-year survival following, in breast cancer, 379, 382
 in high-risk primary breast cancer, 382-384
 in locally advanced breast cancer, 384
 in metastatic breast cancer, 379-381
 overview of, 377-378
HIV infection
 childhood, 204-205
 ocular malignancy in, 203-204
HIV-associated cancer, age-standardized incidence rates of, 204
HMB-45 antigen, 43
Honduras, Pap smear testing in, 194
Hormonal function, acupuncture and, 126
Hormonal therapy, neoadjuvant, in prostate cancer, 8
Hormone receptor status, as prognostic factor, 57
Hormone replacement therapy, 276
Hot flash score, 280
Human papillomavirus, cervical cancer risk and, 190-191
Human saphenous vein angiogenesis assay, 573, 574
Human umbilical vein endothelial cell, 546-547
Hypercalcemia, cancer-related, 285-286
Hypophysectomy, 293

Ibadan, most common tumors in, 203
Ibandronate, 285
ICI-182, 80, 267, 268, 297
Idoxifene, 266, 296
Ifosfamide
 in hepatocellular carcinoma, 515

- Ifosfamide (*Continued*)
 - with taxanes, 348
- IM862, 571, 96
- Image Checker, 222
- Immunologic function, acupuncture and, 126
- Immunomodulatory drug, 603, 607-608
 - differential effects of, 604-605
- Immunotherapy, 337
- India
 - oral cancer in, 169
 - tobacco in, and oral cancer, 169-171
- Insulin-like growth factor 1, 254
- Interferon
 - in hepatitis prevention, 446
 - in hepatocellular carcinoma, 507-508
- Interferon, fluorouracil regimen, in hepatocellular carcinoma, 515
- Interferon therapy, in hepatocellular carcinoma, 518
- Interferon-alfa, 96
- Interferon-alfa-2a, 98
- Interferon-alpha, 571
- Interferon-alpha 2b, cisplatin regimen, 515
- Interferon-alpha 2b, cisplatin, doxorubicin, fluorouracil regimen, 516-517
- Interferon-alpha 2b, cisplatin, methotrexate, fluorouracil regimen, 515
- Interferon-alpha 2b, doxorubicin, cisplatin, fluorouracil regimen, 515
- Interleukin-12, 571, 96, 97
- International Breast Cancer Intervention Trial, 257
- International Council for Establishment and Development of Oncology Centers, 141
- Intra-arterial chemotherapy, hepatic, in hepatocellular carcinoma, 504
- Intraoperative mapping
 - probe-directed, 47-48
 - radiotracer for, 43-45
- Iodine-125, 70
- Iodine-131, 70
- Ionic agitation, 491
- Ipsilateral breast tumor recurrence
 - prognostic factors for, 414
 - relative risk of, 409-410
- Iran, esophageal cancer in, 153
- Iressa, 571
- Irinotecan, 351-352, 37
 - with taxanes, 348
- Isosulfan blue, 48
 - side effects of, 232
- Jamaica, Pap smear testing in, 194
- Kaplan-Meier analysis, 240
- Kaposi's sarcoma
 - age-specific incidence of, in Uganda, 200
 - AIDS-associated, epidemiology of, 200-201
 - pathology of, 201
 - in sub-Saharan Africa, 199-200
- Ki-67, 57-58
- Kidney cancer, Neovastat in, 624
- Knudson hypothesis, 421
- Lagios criteria, ipsilateral breast tumor recurrence and, 414
- Laser-induced thermotherapy, 493
- Latin America
 - cervical cancer in, 188
 - human papillomavirus in, 191
 - mouth cancer in, 159
 - Pap smear testing in, 194
 - pharyngeal cancer in, 159
- Leavell's levels of prevention, 213, 214
- Letrozole, 268, 299-300, 318-319
- Leucovorin, 37
 - fluorouracil plus, 32-35
- Leukemia
 - as angiogenesis-dependent disease, 536, 537
 - associated with adjuvant chemotherapy, 370-372
 - secondary, in breast cancer, 25-26
- Leukopenia, 34
- Leukoplakia, 112-116
- Leuprolide, 323
- Levamisole, in colorectal cancer, 31-32
- LeVeen multiple array radiofrequency needle electrode, tennine, 491
- Level of evidence, 54, 61
- Li-Fraumeni syndrome, breast cancer risk and, 423
- Life expectancy, of women, 362
- Lifestyle modification, in cancer prevention, 253
- Lime, 170
- Lipiodol
 - in computed tomography, 464
 - radio-labeled, 478
- Liposomal anthracycline, 348-349
- Liposomal daunorubicin, in hepatocellular carcinoma, 515
- Liver disease, chronic, prevention of, 522
- Liver function, Child-Pugh classification system of, 475
- Liver transplantation, 447
 - in hepatocellular carcinoma, 479-481
- Lobular carcinoma in situ, tamoxifen and, 262
- Locoregional failure
 - following mastectomy, 246-248
 - rates of, and therapy, 248-249
- Loxoxantrone, 348
- Lumpectomy
 - performance of, 393
 - radiotherapy following, 404
 - with tamoxifen and radiotherapy, 407, 411
- Lung cancer
 - air pollution and, 148
 - arsenic and, 147
 - in Brazil, 143-144
 - Brazilian incidence of, 143-144
 - Brazilian mortality due to, 143-144
 - Brazilian smoking and, 145-147
 - Neovastat in, 623-624
 - occupation and, 147-150
 - risk factors for, 144-145
 - South American incidence of, 144
 - South American mortality due to, 144, 145
- Luteinizing hormone-releasing hormone
 - in neoadjuvant therapy trials, 9
 - in prostate cancer, 8

- Luteinizing hormone-releasing hormone agonist, in ovarian ablation, 315
 LY 353381, 267
 Lymph duct, 229
 Lymph node, physiology of, 229-231
 Lymph node micrometastasis, 58-59
 Lymph node status, in cancer, v bone marrow staging, 241
 Lymphatic invasion, as prognostic factor, 56-57
 Lymphatic nodal status, axillary, and neoadjuvant chemotherapy, 392-396
 Lymphatic vessel, schematic of, 231
 Lymphoscintigraphy, preoperative, 43
- Macronex-160, 540
 MAGE-1, 80
 Magnetic resonance imaging
 of breast, 224-225
 of fibrolamellar hepatocellular carcinoma, 468
 in hepatocellular carcinoma, 461, 462, 463, 464, 465-467
 of nodular lesions, in cirrhosis, 466-467
 Mapping, lymph node, 230-231
 Margin width, ipsilateral breast tumor recurrence and, 414
 Marimastat, 96, 98, 571
 Marker
 of angiogenesis, 60-61
 of cell cycle regulation, 63
 of cell death, 63
 differentiation, 111
 genomic, 111
 of invasion, 61
 of metastasis, 61
 predictive, 306-307
 of proliferation, 57-58, 111
 Markov model, 429
 Mast cell, angiogenesis and, 548-549
 Mastectomy
 locoregional failure following, 246-248
 modified radical, and chemotherapy, 247
 prophylactic, 253, 428
 Mate, 145
 Matrigel rat aortic ring angiogenesis assay, 571, 572-573
 Maturity index, in Brazilian smoking, 146-147
 Mayo Clinic, criteria of, in myeloma, 561
 Measles virus protein F, 337
 Measles virus protein H, 337
 Megestrol acetate, 279-280, 301
 Melacine, 76
 Melanoma, incidence of, 68
 Melanoma-associated marker, 43
 Menopausal symptom, management of, in breast cancer survivors, 279-281
 Menopause
 adjuvant chemotherapy and, 370-372
 breast cancer and, 277
 chemotherapy and, 275
 definition of, 274-277
 peri-, 274
 post-, 274
 pre-, 274
 premature, 274
 Metallothionein, ipsilateral breast tumor recurrence and, 414
- Metastasis, aggressive therapy of, 37-38
 Methotrexate
 adjuvant, 25
 in breast cancer, 14-15
 doxorubicin, cyclophosphamide regimen v, 334
 in early-stage breast cancer, 316
 HER-2 overexpression and, 332-333
 in metastatic breast cancer, 17
 in postmenopausal women, 360-362
 preoperative, in breast cancer, 334
 20-year results following, 16
 Methotrexate, cyclophosphamide, fluorouracil, prednisone, tamoxifen regimen, 249
 Methotrexate, cyclophosphamide, fluorouracil regimen, 248-249
 Methotrexate, fluorouracil, cisplatin, interferon-alpha 2b regimen, 515
 Methoxyestradiol, 571
 Methoxyisobutyl-isonitrile, 225-226
 Methyl-CCNU, doxorubicin, fluorouracil regimen, 515
 Mexico, Pap smear testing in, 194
 MF11-30, 83
 Microcalcification, ipsilateral breast tumor recurrence and, 414
 Micrometastasis, 238
 detection of, 58
 Micronuclei, 111-116
 Microvessel area, 544
 Microvessel count, 60
 Microvessel density, 60-61
 as antiangiogenic therapy marker, 538-539
 poor prognosis and, in multiple myeloma, 565-566
 Microwave coagulation therapy, 493
 Mind-body approach, in breast cancer, 124
 Minimal residual disease, prognostic impact of, 238-240
 Mitomycin
 in hepatocellular carcinoma, 504
 preoperative, in breast cancer, 334
 Mitomycin, doxorubicin, fluorouracil regimen, 515
 Mitotic index, 57
 Mitoxantrone, 515
 in hepatocellular carcinoma, 504, 514
 preoperative, in breast cancer, 334
 with taxanes, 348
 MMP-2, 548
 MMP-9, 548
 Modeling study, 456-457
 Monoclonal antibody 3F8, 69
 Monoclonal antibody 96.5, 69
 Monoclonal antibody D612, 69
 Monoclonal antibody L6, 69
 Monoclonal antibody L72, 69
 Monoclonal antibody(ies), unlabeled, passive therapy with, 68-70
 Monoclonal gammopathies of undetermined significance
 bone marrow angiogenesis in, 543-544
 Mayo Clinic criteria for, 561
 Mouth cancer
 familial clusters in, 166
 genetic susceptibility to, 166
 incidence patterns in, 158-160

- Mouth cancer (*Continued*)
 mortality patterns in, 160-162
 risk factors for, 163
 survival patterns in, 162
- MRI, *see* Magnetic resonance imaging
- MTA, 350
- MUC1, 79
- Mucin, 79
- Mucositis, associated with adjuvant chemotherapy, 370-372
- Muir-Torre syndrome, breast cancer risk and, 423
- Multifocality, ipsilateral breast tumor recurrence and, 414
- Multiple myeloma, 287-288
 angiogenesis in, 561-562
 bone marrow angiogenesis in, 543-544
 characterization of, 551, 560, 565
 Mayo Clinic criteria for, 561
 microvessel density in, as prognostic marker, 536-537
 Neovastat in, 624
 new treatment approaches to, 535
 nuclear factor-kB in, 627
 polymorphisms in, 628
 refractory, thalidomide in, 584-585, 588-591
 thalidomide therapy in, 537-538
 therapy of, and bone marrow angiogenesis, 562-563
 total therapy in, 566
 vascular endothelial growth factor in, 611
- Multiple Outcome of Raloxifene Evaluation, 258
- Mustard prodrug, 339
- Mutation carrier, surveillance for, 427-428
- Myeloma, 287
 thalidomide in, 563
- Myelosuppression, colony-stimulating growth factor and, 18
- N-acetylcysteine, 102
 as chemopreventive agent, 109
- National Cancer Control Program, 141
 in India, 171
- National Cancer Institute, 140
- Nausea, acupuncture and, 125
- Neoadjuvant chemotherapy, 393
 adjuvant v, 394
 axillary nodal status and, 392-396
 current role of, 396-397
 European randomized trials of, 391-392
 future directions with, 397
 nonrandomized trials of, in breast cancer, 390-391
 overview of, 389-390
 preoperative, 334
 prognosis and, 64
 surgical considerations following, 395-396
 US randomized trials of, 392-396
- Neoadjuvant therapy
 in breast cancer, 20-24
 in hepatocellular carcinoma, 477-478
- Neovastat, 96, 571, 621
 antiangiogenic activity of, 621
 antitumoral activity of, 622-623
 clinical studies of, 623
 in multiple myeloma, 624
 phase III clinical trials of, 623-624
 toxicology of, 623
- Neuropathy, associated with adjuvant chemotherapy, 370-372
- Neutropenia, 34
- Newcastle disease virus, 340-341
- Nodule, in cirrhosis, 461-462
- Nolatrexed, in hepatocellular carcinoma, 515
- Non-Hodgkin's lymphoma
 features of, 202
 incidence of, in Uganda, 202
 in sub-Saharan Africa, 201-202
- Nottingham classification, ipsilateral breast tumor recurrence and, 414
- Nuclear factor-kB, 614-615
 activation pathway of, 615
 in multiple myeloma, 627
- Nucleolar grade, ipsilateral breast tumor recurrence and, 414
- Nutrition, as cancer risk factor, 164-165
- Occupation
 as cancer risk factor, 165-166
 lung cancer and, 147-150
- Octreotide, in hepatocellular carcinoma, 509
- Ocular malignancy, in HIV infection, 203-204
- Oil, iodized, in computed tomography, 464
- Omega-3 fatty acids, 123
- Oncogene down regulation, trials of, in cancer, 337
- Oncolytic virus, 340-341
- Onion skinning, of cancer tumor, 338
- Oophorectomy, 293
 prophylactic, 428
 surgical, in early-stage breast cancer, 322, 323
- Oral cancer
 age-adjusted incidence rates of, 172
 control programs for, 171-172
 in India, 169
 pathogenesis of, 171
 screening for, 172-173
 treatment of, 173
- Oral contraceptives, cervical cancer and, 192-193
- Oral health, cancer risk factors and, 166
- Oral hygiene, cancer risk factors and, 166
- Orthotopic liver transplantation, 479-481
- Osteolysis, 286
- Osteoporosis
 raloxifene and, 264
 relative risk for, 276
- Ovarian ablation
 chemotherapy plus, 327-328
 chemotherapy v, 326-327
 clinical trials assessing, 326
 in early-stage breast cancer, 314-315
 history of, 322
 long-term morbidity of, 329
 methods of, 322-324
 overview analysis of, 324-326
 radiation-induced, 323
 tamoxifen plus, 328-329
 in total estrogen blockade, 315
- Ovarian cancer, chemoprevention of, 429
- Ovarian suppression, medical, 323
- Oxaliplatin, 352

- p53, 26, 63
p97, 71
Paclitaxel, 26
 in adjuvant regimens, 18
 in advanced breast cancer, 365-366
 dosing of, 345
 in hepatocellular carcinoma, 515
 scheduling of, in metastatic breast cancer, 346
 weekly, phase II trial of, 347
Pain, acupuncture and, 125-126
Pamidronate, 285, 286-287
Panax ginseng C.A. Meyer, 129
Pap smear testing
 for cervical cancer, 193-195
 in Latin America, 194
Parity, cervical cancer and, 192
Parmigiani model, 426
Patent Blue V, 232
Pentoxifylline, 540
Peptide vaccine, 72, 79-80
Percutaneous biopsy, guided, 468-469
Percutaneous ethanol injection, 481
 in hepatocellular carcinoma, 487, 505
Peripheral blood mononuclear cell, 80
Peripheral blood progenitor cell transplantation, 377-378
Peutz-Jeghers syndrome, breast cancer risk and, 423
Pharyngeal cancer
 in Caribbean, 159
 in Latin America, 159
 mortality patterns in, 161-162
 risk factors for, 163
 survival patterns in, 162
Phase II trial, of herbal regimen, 131
Phytohemagglutinin, 126
PIAF regimen, in hepatocellular carcinoma, 516-517
Plasma cell, angiogenic capacity of, 546-547
Plasma cell labeling index, 562
Ploidy, 57
Point counting, 544
Polychemotherapy
 in breast cancer, 15
 overview of, 359-360
 risk reduction and, 360
Polymerase chain reaction, reverse-transcriptase, 43
Polyvalent melanoma cell vaccine, 75
Polyvalent shed antigen vaccine, 72, 77
Positron emission tomography, 226
Postmastectomy radiotherapy, clinical trial results of, 245-246
Postmenopausal Estrogen Progestin Intervention Trial, 278, 279
Postmenopausal women
 breast cancer therapy in, 360-362
 ER+, chemotherapy clinical trials in, 361
Prediction-based clinical trial, 307-308
 discovery phase of, 308
 feasibility of, 308-309
 validation phase of, 308
Predictive marker, 306-307
Prednisone, in chemotherapy regimen, for breast cancer, 16
Prednisone, cyclophosphamide, methotrexate, fluorouracil, tamoxifen regimen, 249
Premenopausal women
 5-year tamoxifen effect in, 317
 ovarian ablation in, 314-315
Prodrug, 349-350
 with diffusible toxic metabolites, 339
Progesterone receptor, ipsilateral breast tumor recurrence and, 414
Progesterone receptor-negative tumor, 314
Progesterone receptor-positive tumor, 313-314
Progestin, 293, 301
Prognostic factor(s)
 angiogenesis and, 94-95
 in breast cancer, 53-55
 classification of, 54-55
 evaluation of, 54
 proven breast cancer, 55
 strength of, 55
 studies of, 239
Prognostic marker
 bone marrow angiogenesis as, 549-550
 microvessel density as, 536-537
Proliferating cell nuclear antigen, 57-58
Proliferation marker, 111
Prostate cancer
 adjuvant hormonal therapy studies in, 5-7
 adjuvant therapy in, 3-4
 adjuvant therapy theoretical basis in, 4
 neoadjuvant therapy in, 8-10
 preclinical adjuvant therapy basis in, 4-5
 prognostic factors in, 4
Prostatectomy
 in neoadjuvant therapy trials, 9
 neoadjuvant therapy trials prior to, 9
 radical, in prostate cancer, 6-7
Proteasome
 function of, 613-614
 inhibition of, 614-615
 20S, 614
 26S, 613, 614
Proteasome inhibitor, 608-610
PS-341, 613, 629-630
 chemotherapy and, 630
 clinical studies of, 616-617
 effects of, 609
 preclinical studies of, 615-616
PTK787, 571
Puerto Rico, Pap smear testing in, 194
Quality-adjusted life years, 456
Quid, 170
Quinacrine, 540
Radiation, ovarian ablation induced by, 323
Radiation therapy
 adjuvant therapy trials following, 7
 in hepatocellular carcinoma, 505-506
 neoadjuvant therapy trials prior to, 10
 in prostate cancer, 7
 sequencing of, and chemotherapy, 24-25
Radioactive tracer
 for sentinel node identification, 231-232

- Radioactive tracer (*Continued*)
 side effects of, 232
- Radiofrequency ablation
 in hepatocellular cancer, 481-482, 491-493
 of hepatic malignancy, 490-491
- Radioimmunodiagnosics, 70-72
- Radioimmunotherapy, 70-72
- Radioisotope, 225-226
 intraoperative mapping using, 43-45
 for radioimmunotherapy, 70
- Radiotherapy
 in esophageal cancer, 155
 following lumpectomy, 404
 with lumpectomy and tamoxifen, 407, 411
 postmastectomy, clinical trial results of, 245-246
- Raloxifene, 296-297, 317-318
 as breast cancer preventive, 264-265
 clinical trial of, 257
 effect of, on other tissues, 265
 osteoporosis and, 264
 structure of, 267
- Raloxifene Use for the Heart Trial, 265
- Rat aortic ring angiogenesis assay, 571, 572-573
- Recall, in carcinoma surveillance, 453-454
- Recombinant viral vaccine, 72
- Reovirus, 340
- Retinoic acid receptor, 109
- Retinoid-X-receptors, 109
- Retinoids, as chemopreventive agents, 108-109, 110
- Reverse-transcriptase polymerase chain reaction, 43
- Risedronate, 285
- Risk Assessment Tool, 256
- Risk disk, 256
- Rolipram, 540
- Royal Marsden Trial, 257, 262
- S-100 protein antigen, 43
- S-phase, ipsilateral breast tumor recurrence and, 414
- S-phase fraction, 57-58
- Saphenous vein angiogenesis assay, human, 573, 574
- Sawdust, 171
- Schistosomiasis, in Egypt, 174
- Screening
 criteria for, in hepatocellular carcinoma, 450
 for cervical cancer, 193-195
- Selective cytokine inhibitory drug, 603
- Selective estrogen receptor downregulator, 267-268, 319
- Selective estrogen receptor modulator, 260, 294-297, 314, 318
 new, 265
- Selenium, as chemopreventive agent, 109
- Sentinel lymph node biopsy, history of, 229
- Sentinel lymph node dissection
 accuracy of, 49
 in breast cancer, 45-50
 in melanoma, 46
 next phase in, 49-50
 postoperative adjuvant chemotherapy and, 48-49
 success rate of, 49
- Sentinel lymphadenectomy, 41
 dye-directed, 43
- Sentinel node, histopathologic examination of, 48
- Sentinel node surgery
 active clinical trials of, 234
 clinical trials of, 233-234
 methods of, 231-232
- Sentinel node technology, 42-43
- Sexual behavior, cervical cancer and, 191-192
- Silica, Brazilian worker exposure to, 149
- Single-chain antibody, trials of, in cancer, 337
- Skin reaction, delayed-type hypersensitivity, 74
- Smoking
 in Brazil, 145-147
 cervical cancer and, 193
- Smoking habit, 146-147
- Smoldering myeloma, Mayo Clinic criteria for, 561
- Solid tumor, secondary, in breast cancer, 25-26
- Sonograph, General Electric, 221
- Sonography
 in hepatocellular carcinoma, 463, 464
 in hepatocellular carcinoma surveillance, 453
- South America
 cancer incidence rates in, 159
 hepatocellular carcinoma incidence in, 180
 lung cancer incidence in, 144
- Southern blot assay, 60
- Soy, 123, 124
- Spirulina fusiformis*, 110
 as chemopreventive agent, 109
- Squalamine, 96, 571
- Squamous cell carcinoma, HIV-related, pathologic features
 of, 204
- Stem cell transplantation, hematopoietic, *see* Hematopoietic
 stem cell transplantation
- Stomatitis, 34
- Study of Tamoxifen and Raloxifene, 257, 297
- Study of Women Across the Nation, 276
- SU5416, 96, 98, 571
- SU6668, 96, 571
- Sub-Saharan Africa
 AIDS-associated cancers in, 198-199
 anal cancer in, 203
 cervical cancer in, 202-203
 data problems in, 199
 non-Hodgkin's lymphoma in, 201-202
- Subset effect, 305-306
- Sulfur colloid, radio-labeled, 48
- Surgery
 breast-conserving, increasing rate of, 394
 in esophageal cancer, 155
 for ovarian ablation, in early-stage breast cancer, 322, 323
- Surveillance
 efficacy of, 456
 enhanced follow-up *v.*, 450-451
 in hepatocellular carcinoma, 450
 obstacles to, 457
 rationale for, 457
 reduced mortality and, 455
- Survival, and neoadjuvant chemotherapy, 393
- T-cell, activation of, 73
- T-lymphocyte, cytotoxic, 73
- TAG-72, 71

- Tambaku, 170
- Tamoxifen, 278, 293, 295-296, 396
as breast cancer therapy, 260-261
breast cancer and, 254
in breast cancer prevention, 261-263
chemotherapy and, in early-stage breast cancer, 318
chemotherapy plus, 18
clinical trials of, 326
dose intensification of, 364-365
in early-stage breast cancer, 315-318
effects of, 263-264
in ER+ PR+ tumors, 313-314
in ER-PR+ tumors, 313-314
5-year effect of, 317
in hepatocellular carcinoma, 507, 517-518
HER-2 gene amplification and, 314
international randomized trials of, 14
key trials of, 316
locoregional failure and, 249
with lumpectomy and radiotherapy, 407, 411
luteinizing hormone-releasing hormone agonist plus, in
ovarian ablation, 315
neoadjuvant, 392
nonprotocol, guidelines for, 372
ovarian ablation plus, 328-329
in postmenopausal women, 360-362
prevention studies with, 256-257
raloxifene and, 257
risk reduction and, 360
subclinical breast cancer and, 255
therapy with, 255-256
in total estrogen blockade, 315
- Tamoxifen, cyclophosphamide, methotrexate, fluorouracil,
prednisone regimen, 249
- Taxane, 345
in combination regimens, 347-348
side effects of, 347
weekly, phase II trial of, 347
- Tea, green, 123
- Technetium-99, side effects of, 232
- Technetium sulfur colloid, 231
- Tegafur, 349, 350, 508
- Teleradiology, 221-222
- Teleradiology system, schematic of, 223
- Thalidomide, 96, 98, 509, 540, 571 (*Continued*)
actions of, in multiple myeloma, 608
as angiogenesis inhibitor, 537-538
in combination therapy, 579-581
derivatives of, 607-608
dexamethasone plus, 585-586
differential effects of, 604-605
disease applications for, 603
effects of, on cytokines, 600
efficacy of, and microvessel density, 538-539
in hepatocellular carcinoma, 515
in vitro effects of, 602-604
mechanism of action of, 583, 597-600
in myeloma, 563
neuropathy and, 594-595
phase II trial of, 578
potential strategies for, in multiple myeloma, 586
- Thalidomide, 96, 98, 509, 540, 571 (*Continued*)
in refractory multiple myeloma, 584-585, 588-591
remission and, 594
as single agent therapy, 577-579
stem cell collection and, 593-594
structure of, 598
toxicity of, 591
- Thallium 201, 225-226
- Thermotherapy, in hepatocellular carcinoma, 506
- Thiotepa
in chemotherapy regimen, for breast cancer, 16
high-dose, 19
- Three-aminothalidomide, 599
- Thromboembolic disease, associated with adjuvant
chemotherapy, 370-372
- Thymidine labeling index, 57
- Tiludronate, 285
- TLC D-99, 348-349
- TNM stage, as prognostic factor, 55
- TNP-470, 95, 98, 509, 571
- Tobacco
as cancer risk factor, 162-164
chewing, 170
dried, 170
as oral cancer cause, 169-171
- Tomudex, 350
- Topotecan, 351-352
with taxanes, 348
- Toremifene, 265-266, 296, 318
- Total estrogen blockade, 315
- Total therapy, 581
in multiple myeloma, 566
- Transarterial chemoembolization, in hepatocellular
carcinoma, 477-478
- Transgene, antitumor efficacy of, 338
- Transplantation
for hepatocellular carcinoma, 500
peripheral blood progenitor cell, 377-378
- Trastuzumab
chemotherapy and, 352-353
potential value of, 366-367
with taxanes, 348
- TriGem, 84
- Triptorelin, 323
- Tumor, size of
ipsilateral breast tumor recurrence and, 414
and locoregional failure, 248
as prognostic factor, 56
- Tumor blush, 467
- Tumor cell
allogeneic, 75-77
autologous, 74-75
genetically modified, 77-78
- Tumor grade, as prognostic factor, 56
- Tumor growth factor alpha, 254
- Tumor growth factor beta, 254
- Tumor Marker Utility Grading System, 54
- Tumor necrosis factor-alpha, 101, 539-540, 598
role of, in multiple myeloma, 610
as therapeutic target, 610
- Tumor type, as prognostic factor, 56

- Tumor-associated antigen, 76
Tumor-infiltrating lymphocyte, 78
Tumor-node-metastasis stage, as prognostic factor, 55
Tumor-suppressor gene, trials of, in cancer, 337
Tyrosinase, 43
Tyrosinemia, 444, 446-447
- UFT, in hepatocellular carcinoma, 508
- Uganda
 cervical cancer in, 203
 HIV-associated cancer in, 204
 Kaposi's sarcoma incidence in, 200
 non-Hodgkin's lymphoma incidence in, 202
- Ultrasound, of breast, 223-224
- Union Internationale Contre le Cancer, 141
- United States, HIV-associated cancer in, 204
- Upper aerodigestive tract
 chemopreventive agents for, 108
 second primary tumors of, 106-107
 secondary chemoprevention of, 107-108, 111-116
- Uracil, 36, 508
- Urokinase plasminogen activator system, 62-63
- Uruguay, occupation in, and lung cancer, 148
- Vaccine(s), 72-73
 characteristics of, 72
 recombinant, expressing carcinoembryonic antigen, 81-82
- Vaccinia melanoma cell lysate, 77
- Vaccinia melanoma oncolysate, 76-77
- Vaginal dryness, 280
- Van Nuys Prognostic Index, 414
- Vascular endothelial growth factor, 61, 93, 508
 angiogenesis and, 536
 as survival factor, 553
 as therapeutic target, 610-611
 immunohistochemical detection of, 556
 in hematopoietic tumor cell lines, 554
 in multiple myeloma, 554-555
 paracrine effects of, 553-554
- Vascular endothelial growth factor, 61, 93, 508 (*Continued*)
 receptors of, 552
 role of, in multiple myeloma, 554, 611
 in tumor angiogenesis, 552
- Vascular endothelial growth factor receptor, 55
- Vascular invasion, as prognostic factor, 56-57
- Vascular targeting, 97
 as cancer neoadjuvant therapy, 101
- Vascularity, as prognostic marker, 536-537
- Vector transduction, specificity of, 338
- Vector-directed cell lysis, trials of, in cancer, 337
- Venlafaxine, 280
- Vinblastine
 in chemotherapy regimen, for breast cancer, 16
 in hepatocellular carcinoma, 515
- Vincristine, in chemotherapy regimen, for breast cancer, 16
- Vinorelbine, 350-351
 in metastatic breast cancer, 351
 with taxanes, 348
- Viral oncolysate, 72
- Virus, cancer risk and, 166
- Vitamin A, 112, 114-115, 123
 as chemopreventive agent, 109, 110
- Vitamin C, 123
 as chemopreventive agent, 109, 110
- Vitamin E, as chemopreventive agent, 109, 110
- Vitaxin, 97, 98, 571
- VNP20009, 341
- Vomiting, acupuncture and, 125
- von Hippel-Lindau gene, 102
- Vorazole, 300
- Women, life expectancy of, 362
- World Health Organization, 213-215
- YM175, 288
- Yttrium-90, 70
- Zimbabwe, HIV-associated cancer in, incidence rates for, 204
- Zoledronate, 288

